Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eduardo Kleer

Urology Ypsilanti, MI Medical Doctor

NPI 1831195304 CMS profile 899334

5333 McAuley Dr, Ste 3001, Ypsilanti, MI 48197

Open in the dashboard

General payments

$2,067

23 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eduardo Kleer of Ypsilanti, MI is reported in the CMS Open Payments database as having received $2,067 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121 5
2024 General $1,272 8
2023 General $375 5
2022 General $103 2
2021 General $28 1
2019 General $168 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eduardo Kleer
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Eduardo Kleer were reported at $121. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Eduardo Kleer Urology median Middle half National median
2019 $168 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $28 $358 $111–$1,000 $132
2022 $103 $476 $143–$1,263 $149
2023 $375 $560 $168–$1,461 $160
2024 $1,272 $563 $170–$1,464 $164
2025 $121 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. PROCEPT BioRobotics Corporation $1,154 8 payments
  2. Coloplast Corp $252 3 payments
  3. Novocure Inc. $163 1 payment
  4. Tempus AI, Inc $123 1 payment
  5. Terumo Medical Corporation $113 1 payment
  6. Richard Wolf Medical Instruments Corp. $67 1 payment
  7. Boston Scientific Corporation $58 2 payments
  8. AstraZeneca Pharmaceuticals LP $35 1 payment
  9. Olympus America Inc. $30 1 payment
  10. Dornier MedTech America, Inc $28 1 payment
  11. Other $44 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,277 20 payments
  2. Travel and Lodging $754 2 payments
  3. Education $35 1 payment
Products named General payments · program years 2019–2025
  1. AQUABEAM SYSTEM $1,008 5 payments
  2. Azur CX Detachable $227 2 payments
  3. Porges Coloplast $167 2 payments
  4. Optune $163 1 payment
  5. ANGIO-SEAL $113 1 payment
  6. AQUABEAM ROBOTIC SYSTEM Urology $102 1 payment
  7. AQUABEAM ROBOTIC SYSTEM Urology $44 2 payments
  8. IMFINZI $35 1 payment
  9. iTIND System $30 1 payment
  10. AMS 800 Artificial Urinary Sphincter $28 1 payment
  11. Other $47 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,487

Median for Urology: 1,053

Drug cost

$41,359

Median for Urology: $101,464

Branded share of claims

17.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 500 $14,371
Finasteride Generic 337 $6,815
Tadalafil Generic 72 $6,795
Oxybutynin Chloride Er Oxybutynin Chloride Brand 99 $3,762
Alfuzosin Hcl Er Alfuzosin Hcl Brand 76 $2,892
Testosterone Generic 14 $1,084
Terazosin Hcl Generic 32 $991
Solifenacin Succinate Generic 17 $860
Testosterone Cypionate Generic 20 $773
Bicalutamide Generic 21 $700

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$134,843

Of which drugs: $19,934

Medicare patients

489

Average age 76

Services billed

2,493

37 women, 452 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Cancer 44%
Arthritis 36%
Ischemic heart disease 32%
Chronic kidney disease 27%
Diabetes 23%
Atrial fibrillation 19%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 17 115 $16,111

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record